Compare Hinge Health Inc. Class A Common Stock (HNGE) vs Kinross Gold Corporation (KGC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hinge Health Inc. Class A Common Stock vs Kinross Gold Corporation — how do they compare? Hinge Health Inc. Class A Common Stock trades at $104.95 (market cap $8.48B), while Kinross Gold Corporation trades at $22.4 (market cap $27.68B). The key difference: Kinross Gold Corporation is far larger — about 3.3× Hinge Health Inc. Class A Common Stock's market cap, and Kinross Gold Corporation pays a 0.68% dividend while Hinge Health Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hinge Health Inc. Class A Common Stock for 0 Days and Kinross Gold Corporation for 53 Days on average.
| HNGE | KGC | |
|---|---|---|
Market Cap | $8.48B | $27.68B |
Volume | 879,799 | 5,395,404 |
Sector | Health | Basic Materials |
52-Week High | $105.14 | $38.06 |
52-Week Low | $31.17 | $22.24 |
Typical Hold Time | 0 Days | 53 Days |
Enterprise Value | $8.10B | $25.76B |
Dividend Yield | — | 0.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
Kinross Gold (KGC) trades at $22.24, down 5.56% amid production guidance cuts and legal investigations, yet maintains strong fundamentals with robust earnings beats and a 37.52% net margin. Technical indicators show bearish momentum with support at $23, while fundamentals reveal impressive revenue growth from $3.5B in 2022 to $7.05B in 2025, supported by a low P/E of 8.91 and rising cash flow.
The stock presents a value opportunity with a consensus price target of $38.80 (74% upside), but faces near-term headwinds from operational setbacks and legal scrutiny. Long-term prospects remain solid due to gold price strength and shareholder returns, though investors must weigh production risks against valuation appeal.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hinge Health Inc. Class A Common Stock
Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →About Kinross Gold Corporation
Kinross Gold is a Canada-based senior gold producer, producing roughly 2.4 million gold equivalent ounces in 2020. The company had 30 million ounces of proven and probable gold reserves and 59 million ounces of silver reserves at the end of 2020. It operates mines and focuses its greenfield and brownfield exploration in the Americas, West Africa, and Russia. The company has historically used acquisitions to fuel expansion into new regions and production growth.
Read more on KGC →
